Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 161-170 of 220 for Multiple Myeloma

Edit search filters
  1. Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

    Scottsdale/Phoenix, AZ

  2. Study of INCB053914 in Subjects With Advanced Malignancies

    Jacksonville, FL

  3. MC230818 Understanding the mechanisms of clonal and non-clonal cytopenia following CAR-T therapy (MC230818)

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  4. Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  5. A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors

    Rochester, MN, Jacksonville, FL

  6. A Study to Evaluate MEDI2228 in Subjects with Relapsed/ Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

    Rochester, MN, Jacksonville, FL

  8. Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)

    Rochester, MN

  9. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies

    Rochester, MN

  10. Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer